The end of hepatitis C

Clin Gastroenterol Hepatol. 2014 Apr;12(4):533-6. doi: 10.1016/j.cgh.2014.01.025. Epub 2014 Jan 28.

Authors

Norman L Sussman¹, Christopher H Remien², Fasiha Kanwal³

Affiliations

¹ Department of Surgery, Baylor College of Medicine, Houston, Texas.
² National Institute for Mathematical and Biological Synthesis, University of Tennessee, Knoxville, Tennessee.
³ Department of Medicine, Baylor College of Medicine, Houston VA Health Services Research and Development Center of Excellence, Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, Texas.

PMID: 24480676
DOI: 10.1016/j.cgh.2014.01.025

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Antiviral Agents / therapeutic use*
Disease Eradication*
Drug Therapy, Combination / methods
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / epidemiology*
Hepatitis C, Chronic / prevention & control
Humans
United States / epidemiology

Substances

Antiviral Agents